NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HSCS

HeartSciences Inc

Jul 11 • 04:00PM ET

4.16

Dollar change -1.57
Percentage change -27.40	%

Healthcare • Medical Devices • USA • NASD

Peers: JNJ ABT BAX MDT SYK BSX TMO EW RMD ZBH

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-10.21	Insider Own	9.38%	Shs Outstand	1.03M	Perf Week	16.53%
Market Cap	4.49M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.98M	Perf Month	15.88%
Enterprise Value	4.88M	PEG	-	EPS next Q	-	Inst Own	2.17%	Short Float	19.62%	Perf Quarter	36.39%
Income	-8.52M	P/S	-	EPS this Y	-	Inst Trans	36.25%	Short Ratio	3.31	Perf Half Y	16.48%
Sales	0.00M	P/B	2.40	EPS next Y	-	ROA	-103.21%	Short Interest	0.19M	Perf YTD	8.90%
Book/sh	1.73	P/C	1.73	EPS next 5Y	-	ROE	-163.47%	52W High	6.47 -35.70%	Perf Year	-10.92%
Cash/sh	2.41	P/FCF	-	EPS past 3/5Y	14.98% 20.70%	ROIC	-399.39%	52W Low	2.36 76.27%	Perf 3Y	-97.60%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-10.11% -26.63%	Gross Margin	-	Volatility	27.79% 12.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	78.91%	Oper. Margin	-	ATR (14)	0.58	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.80	Sales Y/Y TTM	-100.00%	Profit Margin	-	RSI (14)	52.48	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.98	EPS Q/Q	15.83%	SMA20	6.45%	Beta	2.57	Target Price	12.00
Payout	-	Debt/Eq	1.67	Sales Q/Q	-100.00%	SMA50	11.15%	Rel Volume	10.80	Prev Close	5.73
Employees	15	LT Debt/Eq	0.20	Earnings	Mar 13	SMA200	19.42%	Avg Volume	58.02K	Price	4.16
IPO	Jun 15, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	-10.41% -	Trades		Volume	626,602	Change	-27.40%

Jun-05-25 09:06AM	HeartSciences recesives FDA BDD for Aortic Stenosis ECG algorithm (TipRanks) -5.03%
Jun-04-25 09:00AM	HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis (GlobeNewswire)
Jun-03-25 09:00AM	Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences' Patent Portfolio and IP Value (GlobeNewswire) +6.78%
May-30-25 09:05AM	HeartSciences signs first MyoVista Insights platform customer (TipRanks)
May-29-25 09:00AM	HeartSciences Signs First MyoVista Insights Platform Customer, Marking Major Commercial Milestone (GlobeNewswire)
09:00AM	Loading…
May-20-25 09:00AM	HeartSciences' CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025 (GlobeNewswire) +21.68%
07:00AM	Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream (GlobeNewswire)
May-08-25 09:00AM	HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson (GlobeNewswire)
May-07-25 09:00AM	HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board (GlobeNewswire)
May-01-25 09:00AM	HeartSciences Announces Launch of MyoVista Insights Platform and Related Early Adopter Program (GlobeNewswire)
Mar-13-25 04:15PM	HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Mar-10-25 09:00AM	HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications (GlobeNewswire)
Dec-16-24 04:15PM	HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results (GlobeNewswire)
Nov-13-24 09:00AM	HeartSciences' AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement (GlobeNewswire)
Oct-14-24 04:15PM	HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire) +5.92% -5.03%
04:15PM	Loading…
Sep-12-24 04:15PM	HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results (GlobeNewswire) +8.96%
09:00AM	HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission (GlobeNewswire)
Jul-29-24 04:05PM	HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results (GlobeNewswire) -10.26% -6.81%
Jul-26-24 09:00AM	Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista wavECG Potential to Improve Cardiovascular Pathway Efficiency (GlobeNewswire) +22.13%
Jul-25-24 08:30AM	HeartSciences Selected to Demonstrate MyoVista wavECG at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare (GlobeNewswire)
Jul-11-24 09:00AM	HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction (GlobeNewswire) -8.60%
Jun-04-24 04:15PM	HeartSciences Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -9.49% +7.77%
May-20-24 09:00AM	HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio (GlobeNewswire) -15.64%
May-13-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -19.77%
Apr-24-24 09:00AM	HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG (GlobeNewswire) +9.10%
Apr-02-24 04:15PM	HeartSciences to Present at the LD Micro Invitational XIV Conference (GlobeNewswire) -6.09%
Mar-26-24 09:00AM	HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients (GlobeNewswire)
Mar-14-24 09:54PM	HSCS Stock Earnings: Heart Test Laboratories Beats EPS for Q3 2024 (InvestorPlace) +5.75%
04:15PM	HeartSciences Reports Third Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Mar-12-24 09:00AM	HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes (GlobeNewswire)
09:20AM	Loading…
Mar-06-24 09:20AM	Why Is Heart Test Laboratories (HSCS) Stock Down 21% Today? (InvestorPlace) -27.41%
09:00AM	HeartSciences Announces Canada Patent Grant Covering MyoVista Wavelet Technology (GlobeNewswire)
Feb-26-24 09:00AM	HeartSciences Adds Key Advisor to its Scientific Advisory Board (GlobeNewswire)
Feb-12-24 09:00AM	HeartSciences Expands its Scientific Advisory Board (GlobeNewswire)
Feb-01-24 09:00AM	HeartSciences Appoints New Scientific Advisory Board Member (GlobeNewswire) -5.87%
Jan-18-24 08:00AM	HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting (GlobeNewswire) -17.05%
Jan-03-24 04:15PM	HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting (GlobeNewswire) -6.31%
Dec-18-23 11:52AM	HSCS Stock Earnings: Heart Test Laboratories Misses EPS for Q2 2024 (InvestorPlace) -8.24%
Dec-14-23 04:15PM	HeartSciences Reports Second Quarter Fiscal 2024 Financial Results (GlobeNewswire) +12.09%
Dec-05-23 08:00AM	HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway (GlobeNewswire)
Nov-20-23 08:00AM	HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms (GlobeNewswire) +11.65%
Nov-15-23 08:07AM	Why Is Heart Test Laboratories (HSCS) Stock Up 43% Today? (InvestorPlace) -16.62%
Nov-13-23 08:45AM	HeartSciences' MyoVista wavECGTM Selected for Heart Screening of Irish Garda National Police Officers (GlobeNewswire)
Nov-08-23 07:54AM	Why Is Heart Test Laboratories (HSCS) Stock Up 298% Today? (InvestorPlace) +53.38%
Oct-19-23 09:00AM	HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments (GlobeNewswire)
Sep-26-23 08:00AM	HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio (GlobeNewswire)
Sep-25-23 08:00AM	HeartSciences to Participate in the Maxim Group Virtual Tech Conference Series: Emerging Growth in A.I. (GlobeNewswire) -6.57%
Sep-21-23 08:00AM	HeartSciences Signs Definitive Agreements with the Icahn School of Medicine at Mount Sinai to Commercialize Artificial Intelligence Cardiovascular Algorithms (GlobeNewswire)
Sep-14-23 04:15PM	HeartSciences Reports First Quarter Fiscal 2024 Financial Results (GlobeNewswire)
Sep-12-23 04:15PM	HeartSciences to Present at the Gilmartin Group Emerging Growth Showcase (GlobeNewswire)
Sep-11-23 04:15PM	HeartSciences Named Electrocardiography Advancement Specialists of the Year 2023 - USA in the Global Health & Pharma Excellence Awards (GlobeNewswire)
Sep-07-23 09:00AM	HeartSciences Signs Distribution Agreement with MedPhy Technologies, Mumbai, India (GlobeNewswire)
Aug-31-23 09:00AM	HeartSciences Signs Distribution Agreement with FJ Medical, Denmark (GlobeNewswire)
Aug-24-23 09:00AM	HeartSciences MyoVista® wavECGTM Selected to be used in Irish Heart Screening Evaluation (GlobeNewswire)
Aug-17-23 10:36AM	EXCLUSIVE: HeartSciences Announces Expansion of Artificial Intelligence Patent Portfolio (Benzinga)
09:00AM	HeartSciences Announces Further Expansion of Artificial Intelligence (AI) Patent Portfolio (GlobeNewswire)
Jul-27-23 09:00AM	MyoVista wavECG goes into clinical use at the Naya Imaging Center in Denmark (GlobeNewswire)
Jul-19-23 09:00AM	HeartSciences Provides Business Update and Reports Fiscal 2023 Financial Results (GlobeNewswire) -5.26%
May-17-23 08:00AM	HeartSciences Named as a Top 10 Healthcare Artificial Intelligence Solutions Provider 2023 by Healthcare Tech Outlook Magazine (GlobeNewswire)
May-09-23 08:15AM	HeartSciences Announces Completion of Patient Enrollment for FDA Pivotal Study of MyoVista wavECG (GlobeNewswire)
May-08-23 08:15AM	HeartSciences to Participate at the Inaugural EF Hutton Global Conference (GlobeNewswire)
May-02-23 08:15AM	HeartSciences to Participate in The Benchmark Companys Virtual Individual Investor Healthcare Conference (GlobeNewswire)
Apr-24-23 09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE) -10.11%
Apr-17-23 08:15AM	HeartSciences to Present at the Planet MicroCap Showcase: VEGAS 2023 (GlobeNewswire) +9.10%
Mar-18-23 08:39AM	Heart Test Laboratories Reports Third Quarter 2023 Earnings (Simply Wall St.)
Mar-16-23 04:15PM	HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2023 Financial Results (GlobeNewswire) -8.18% +9.90%
Feb-07-23 11:04AM	HeartSciences CEO Invited as Featured Guest on The Big Biz Show, February 7 at 11:45 a.m. Pacific Time (GlobeNewswire)
Feb-06-23 07:30AM	HeartSciences Granted Key Israeli International Patent for its MyoVista® Wavelet Technology Utilizing Artificial Intelligence (AI) for Early Detection of Heart Disease (GlobeNewswire) -17.65%
Feb-03-23 09:00AM	HeartSciences Announces Further Internationalization of its Patent Portfolio (GlobeNewswire) +139.44%
Jan-24-23 11:00AM	Maxim Group LLC to Host the Healthcare IT Virtual Conference on Wednesday, January 25th at 8:15 A.M. ET (GlobeNewswire)
Jan-23-23 09:00AM	Correction: HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th (GlobeNewswire)
Jan-20-23 09:00AM	HeartSciences CEO to Participate in the Healthcare IT Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest on January 25th (GlobeNewswire)
Jan-04-23 09:00AM	HeartSciences Appoints David R. Wells to its Board of Directors, an Experienced Capital Markets and Finance Executive (GlobeNewswire)
Dec-16-22 08:30AM	HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2023 Financial Results (GlobeNewswire)
Dec-01-22 09:00AM	HeartSciences and Rutgers University Announce Multi-Year Collaboration to Develop AI-based ECG Algorithms (GlobeNewswire)
Nov-28-22 09:00AM	HeartSciences to Present at the 2022 RHK Disruptive Growth Conference on December 5, 2022 (GlobeNewswire) -5.76%
Nov-21-22 09:00AM	HeartSciences to Participate at the Benchmark Discovery One-on-One Investor Conference on December 1, 2022 (GlobeNewswire)
Nov-10-22 09:00AM	HeartSciences MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events (GlobeNewswire)
Oct-25-22 09:00AM	HeartSciences Granted European Patent for Proprietary Electrode and Cable Connections for Use with its AI-Based MyoVista® ECG (GlobeNewswire) +14.02%
Oct-20-22 09:00AM	HeartSciences Named as a Top 10 MedTech Startup 2022 by MedTech Outlook Magazine (GlobeNewswire) +10.13%
Oct-19-22 09:15AM	HeartSciences Announces Major Milestone with the Issuance of CPT® Codes by the American Medical Association for ECG AI Analysis of Cardiac Dysfunction (GlobeNewswire)
08:45AM	EXCLUSIVE: Issuance Of New Reimbursement-Related Codes Validates Commercial Opportunity For HeartSciences' Flagship Product (Benzinga)
Oct-18-22 09:00AM	HeartSciences to Present at the LD Micro Main Event XV on October 26th (Newsfile)
Oct-06-22 09:00AM	HeartSciences to Present at MicroCap Rodeo's Windy City Roundup Conference on October 12th (ACCESSWIRE)
Sep-20-22 08:30AM	HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence (GlobeNewswire)
Sep-13-22 08:00AM	HeartSciences Provides Business Update and Reports First Quarter Fiscal 2023 Financial Results (GlobeNewswire)
Sep-12-22 08:30AM	HeartSciences to Participate and Showcase the MyoVista at the Inauguration Ceremony of the Center for Innovation at Rutgers Robert Wood Johnson University Hospital (GlobeNewswire)
Sep-08-22 08:30AM	HeartSciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-01-22 08:30AM	HeartSciences Provides Corporate Update and Reports Fiscal 2022 Financial Results (GlobeNewswire) +5.04%
Jul-13-22 02:03PM	HeartSciences CEO to Participate in the Benzinga All Access Event on July 15th (GlobeNewswire)
Jun-15-22 09:50AM	Heart Test Laboratories, Inc. Announces Pricing of $6.375 Million Initial Public Offering and Nasdaq Listing (GlobeNewswire)

HeartSciences, Inc. is a medical technology company, which focuses on applying innovative AI-based technology to an electrocardiogram (ECG) to expand and improve an ECG's clinical usefulness. Its objective is to make an ECG a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It offers MyoVista, a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. The company was founded in 2008 and is headquartered in Southlake, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HSCS

HeartSciences Inc

Upgrade your FINVIZ experience